ZimVie Inc

ZimVie — Investor Day (February 2022)

70 slides from ZimVie's investor day presentation, Feb 7, 2022

  1. Slide 1: Investor Day February 7, 2022

    Slide 1: Investor Day February 7, 2022

    Investor Day February 7, 2022

  2. Slide 2: Disclaimer: Forward-Looking Statements and Non-GAAP Measures

    Slide 2: Disclaimer: Forward-Looking Statements and Non-GAAP Measures

    Disclaimer FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES Safe Harbor Statement under the Private Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans

  3. Slide 3: Agenda

    Slide 3: Agenda

    Agenda Time (EST) Topics Presenter 11:00 – 11:05am Welcome Vafa Jamali Introduction to ZimVie CEO 11:05 – 11:30am Business Highlights Indraneel Kanaglekar 11:30am – 12:00pm Overview of Dental Opportunity SVP, President of Global Dental Rebecca Whitney 12:00 – 12:40pm Overview of Spine Opportunity SV

  4. Slide 4: Presenters

    Slide 4: Presenters

    Indraneel Kanaglekar Rebecca Whitney Rich Heppenstall SVP, President, SVP, President, ZimVie Global Dental, Global Spine, Chief Financial Officer ZimVie ZimVie [Graphic Appears Here] [Graphic Appears Here] [Graphic Appears Here] [Graphic Appears Here] Vafa Jamali ZimVie Chief Executive Officer

  5. Slide 5: Why are we spinning off?

    Slide 5: Why are we spinning off?

    Why are we spinning off? To breathe new life, dedicated energy and strategic focus to our trusted brands and products.

  6. Slide 6: Positioned to Capitalize on Multiple Opportunities for Growth

    Slide 6: Positioned to Capitalize on Multiple Opportunities for Growth

    Positioned to Capitalize on Multiple Opportunities for Growth 1 Well-positioned in large and growing ~$20B global dental and spine markets 2 Comprehensive portfolio of trusted brands and products 3 Differentiated product profiles, supported by extensive clinical evidence 4 Established commercial inf

  7. Slide 7: Introduction to ZimVie

    Slide 7: Introduction to ZimVie

    Introduction to ZimVie Vafa Jamali Chief Executive Officer

  8. Slide 8: ZimVie At A Glance

    Slide 8: ZimVie At A Glance

    ZimVie At A Glance ~$20B Global Market Opportunity ~$1B[1] Dental, 46% Third Party 2021E Sales Sales by # Market Player # Market Player (unaudited) Segment 5 6 (2021E) Spine, in Dental in Spine 54% ~66%[2] 20+ Brands Trusted by Clinicians and Surgeons Worldwide Management Adjusted APAC, 12% 2021E Gr

  9. Slide 9: Well Known Brands with Established History

    Slide 9: Well Known Brands with Established History

    Well Known Brands with Established History Spine Dental EBI Pre-2016 2016 2019 2020 2021 2022 Acquisition of LDR to Acquisition of ZimVie becomes take the lead in 3DIEMME to expand independent publicly cervical disc digital dentistry traded company replacement portfolio 1988 1999 2003 2008 2008 Acqu

  10. Slide 10: Vision, Mission and Core Values

    Slide 10: Vision, Mission and Core Values

    Vision Everyone deserves to feel better, healthier, and stronger. We create solutions for people to enjoy and experience life. Mission Advancing clinical technology foundational to restoring daily life. Page 10 Our Core Values uriosity Authenticity Accountability Growth Mindset

  11. Slide 11: Executing the Growth Plan

    Slide 11: Executing the Growth Plan

    Executing the Growth Plan Drive sustainable growth through innovation and market development in focused categories Leverage experienced management team to identify and focus on the best opportunities for growth Strengthen the foundation: strategically, operationally, and commercially

  12. Slide 12: ZimVie Transformation Focused on Value Creation

    Slide 12: ZimVie Transformation Focused on Value Creation

    ZimVie Transformation Focused on Value Creation Build Leadership & Talent Systems & Operations Performance & Innovation ZimVie Pillar  Team engagement scores  Exited unprofitable geographies to  Disciplined portfolio management increased to 80 from 60’s focus on greatest opportunities Op

  13. Slide 13: Business Highlights

    Slide 13: Business Highlights

    Business Highlights Vafa Jamali Chief Executive Officer

  14. Slide 14: Patient Conditions We Serve

    Slide 14: Patient Conditions We Serve

    Patient Conditions We Serve In Our DENTAL An estimated 8 million US patients seek treatment for tooth loss annually Only 25% receive tooth replacement Focus on increasing access to treatments with better outcomes for patients We improve smiles, function, and confidence in daily life Page 14 SPINE Sp

  15. Slide 15: ZimVie is a Leading Player in a Large and Growing ~$20B Market

    Slide 15: ZimVie is a Leading Player in a Large and Growing ~$20B Market

    ZimVie is a Leading Player in a Large and Growing ~$20B Market Opportunity ZimVie Segments Category Market Size ($B) Segment Growth[1] Dental Implant Solutions $5.0 MSD Dental Biomaterials $1.0 MSD Digital Dentistry $2.0 HSD Core and Complex Solutions $8.5 LSD Bone Healing / EBI $0.5 LSD Spine Minim

  16. Slide 16: Dental Capabilities

    Slide 16: Dental Capabilities

    Dental Capabilities Fully Integrated End-to-End Tooth Replacement Solutions Dental Implants ~300 In-House Full range of R&D Employees Tapered T3 Implant™ abutments, Screw-Vent® Across Spine & Dental copings and (TSV) analogs Collaboration with Surgeons, Clinicians, Biomaterials KOLs Xenograft and Ba

  17. Slide 17: Spine Capabilities

    Slide 17: Spine Capabilities

    Spine Capabilities Comprehensive Product Portfolio Core and Complex Solutions ~300 In-House R&D Employees llOss® Virage® Vital™ Across Spine & Dental ROI-C® PrimaGen Advanced™ MaxAn® Allograft Collaboration with Surgeons, Clinicians, Minimally Invasive Surgery Bone Healing / EBI KOLs Timberline® Bon

  18. Slide 18: Platforms Supported by Extensive Clinical Evidence

    Slide 18: Platforms Supported by Extensive Clinical Evidence

    Platforms Supported by Extensive Clinical Evidence – 1,750+ peer-reviewed publications PUROS MOBI-C THE TETHER ALLOGRAFT First PMA-approved cervical The only FDA-approved device Family of allografts, clinically disc in the US. Proven for anterior vertebral body documented to provide statistically su

  19. Slide 19: Global Infrastructure

    Slide 19: Global Infrastructure

    Global Infrastructure 4 Global Headquarters Commercial, Training, R&D Facities 1B Manufacturing Sites U D ae , * q y aad Sales and Distribution ~ Z ’ Dental + 95% of sales are direct, “i + Third party distributors in smaller geographies + Customers: Oral surgeons, ” ‘general dentists, dental labs, D

  20. Slide 20: Focus on Delivering Long-Term Sustainable Growth

    Slide 20: Focus on Delivering Long-Term Sustainable Growth

    Focus on Delivering Long-Term Sustainable Growth Common Market Trends  ging Global PopulationIncreasing Healthcare sumerism ovider Economics Pressures doption of echnology for utcomes ZimVie Growth Objectives Drive Commercial & Operational Focus Improving efficiency, profitability, and c

  21. Slide 21: Proven Executive Leadership Team

    Slide 21: Proven Executive Leadership Team

    Proven Executive Leadership Team Vafa Jamali Rich Heppenstall Heather Kidwell Indraneel Kanaglekar Rebecca Whitney Chief Executive Officer EVP, Chief Financial Officer SVP, Chief Legal and SVP, President, SVP, President, Compliance Officer Global Dental Global Spine Michael Minette Ann Vu David Harm

  22. Slide 22: Experienced Board of Directors

    Slide 22: Experienced Board of Directors

    Experienced Board of Directors Dave King Sally Crawford Vinit Asar Former Chairman and CEO, Former COO, President, CEO and Director, LabCorp Healthsource, Inc. Hanger, Inc. Karen Matusinec Vafa Jamali Former SVP, Treasurer CEO and Director, McDonald’s Corporation ZimVie

  23. Slide 23: Positioned to Capitalize on Multiple Opportunities for Growth

    Slide 23: Positioned to Capitalize on Multiple Opportunities for Growth

    Positioned to Capitalize on Multiple Well-positioned in large and growing ~$20B global dental 1 Opportunities and spine markets for Growth 2 Comprehensive portfolio of trusted brands and products 3 Differentiated product profiles, supported by extensive clinical evidence MSD% Growth 4 Established co

  24. Slide 24: Overview of Dental Opportunity

    Slide 24: Overview of Dental Opportunity

    Overview of Dental Opportunity Indraneel Kanaglekar SVP, President of Global Dental

  25. Slide 25: Leading Dental Player with Strong Momentum

    Slide 25: Leading Dental Player with Strong Momentum

    Leading Dental Player with Strong Momentum ~$8B 3 $469M Global Tooth Submarkets – Implants, Dental 2021E Sales Replacement Market Biomaterials, Digital Dentistry (unaudited) #2 Best-in-Class 57% US Portfolio of Brands Trusted by 43% OUS Global Biomaterials [1, 2] Clinicians and Surgeons Approximate

  26. Slide 26: Tooth Replacement: ~$8B Market Growing at Mid Single Digits

    Slide 26: Tooth Replacement: ~$8B Market Growing at Mid Single Digits

    Tooth Replacement: ~$8B Market Growing at Mid Single Digits Major Trends Shaping Our Industry Market Opportunity Macro: Dental Implant Solutions HSD Biomaterials growth 120M people in the US Digital Dentistry are missing at least one tooth (44% of individuals aged 15+) [1, 2, 3] MSD Aging Increasing

  27. Slide 27: Product Overview

    Slide 27: Product Overview

    Product Overview Key Products Key Competitors Dental Implants Implants, surgical tools, abutments, and other restorative components for implant-based tooth Tapered Screw- Full range of abutments, T3 Implant replacement Vent (TSV) copings, and analogs Biomaterials Bone graft substitutes, membranes, a

  28. Slide 28: ZimVie Dental Growth Drivers

    Slide 28: ZimVie Dental Growth Drivers

    ZimVie Dental Growth Drivers Implant Growth: Biomaterials Digital Dentistry Geographic Innovation & Execution Pull-Through Pull-Through Expansion Increase Penetration of Leverage Leadership Drive Digital Workflow Scale ZimVie Presence Implants through Continued Position to Drive Implant Adoption and

  29. Slide 29: Implant Growth

    Slide 29: Implant Growth

    Implant Growth Drive Implant Growth Through Continuous Innovation and Commercial Execution • Broad and comprehensive portfolio • Proven clinical success Key Highlights • Drives 60%+ of total dental revenue • 10M+ implants sold in the last 10 years • Innovative surface technologies Strategies to Driv

  30. Slide 30: Biomaterials Pull-Through

    Slide 30: Biomaterials Pull-Through

    Biomaterials Pull-Through Leverage Biomaterials Leadership Position • #1 Allograft company [1] • Repairs bone defects Key Highlights • #2 Global biomaterials company [2, 3] • Improved esthetic and clinical outcomes • Implant pull-through Strategies to Drive Implant Growth ZimVie Dental Biomaterials

  31. Slide 31: Drive Implant Penetration Through Digital Dentistry

    Slide 31: Drive Implant Penetration Through Digital Dentistry

    Drive Implant Penetration Through Digital Dentistry Digital Dentistry Pull-Through Mission Increase Patient Access Empower Dentists Better Outcomes Economic Value Bring dental implant therapy Reduce learning curve Increase clinician Improve procedure to underserved markets for dentists skill and pro

  32. Slide 32: Quality End-to-End Workflow Solutions

    Slide 32: Quality End-to-End Workflow Solutions

    Quality End-to-End Workflow Solutions Digital Dentistry Pull-Through Surgical Workflow Restorative Workflow Treatment Plan Surgery Using Guided Kit, Restorative Design Computer Aided Manufacturing Using Software 3D Printed Guide / Using CAD / CAM (CAM) to produce the restoration Template C/T= 10min

  33. Slide 33: Drive Implant Growth via Digital Workflow Adoption

    Slide 33: Drive Implant Growth via Digital Workflow Adoption

    Digital Dentistry Pull-Through Drive Implant Growth via Digital Workflow Adoption Encode® RealGUIDE™ BellaTek ® SmileZ Software Today New Product Introductions Introduce unique new products and workflows focused on simplification of implant procedures and practice optimization: software, workflows,

  34. Slide 34: Geographic Expansion

    Slide 34: Geographic Expansion

    Geographic Expansion Global Presence Enables Opportunistic Geographic Expansion Established Presence and Support Geographic Expansion Strategy Continuing Leverage existing commercial Education & infrastructure in attractive direct and Training indirect geographies Inside Sales Dedicated Reps, Custom

  35. Slide 35: Focused on Meaningful Growth Initiatives in the Near-Term

    Slide 35: Focused on Meaningful Growth Initiatives in the Near-Term

    Focused on Meaningful Growth Initiatives in the Near-Term 2019 – 2021 2022 – 2024 [1] Dental Revenue ($M) Implant • Flagship launches • DSO channel investment Growth • DSO channel expansion Biomaterials • Continued innovation $469 • Innovation Pull-Through • Implant pull-through initiative Drivers $

  36. Slide 36: Dental Key Takeaways

    Slide 36: Dental Key Takeaways

    Dental Key Takeaways • #5 share in an attractive ~$8B global market • Well-positioned business with operating performance momentum • Focused on four key growth drivers:  Implant Growth via Innovation and Execution  Biomaterials Pull-Through Digital Dentistry Pull-Through Geographic Expan

  37. Slide 37: Overview of Spine Opportunity

    Slide 37: Overview of Spine Opportunity

    Overview of Spine Opportunity Rebecca Whitney SVP, President of Global Spine

  38. Slide 38: Leading Spine Player with Significant Growth Opportunity

    Slide 38: Leading Spine Player with Significant Growth Opportunity

    Leading Spine Player with Significant Growth Opportunity ~$12B Market Leader $540M[1] In High-Growth Global Spine Surgery Market Spine 2021E Sales Sub-segments (unaudited) Broad Portfolio 750+ 70% US Of Spine Products Designed to 30% OUS Meet the Needs of Surgeons Clinical Publications & Approximate

  39. Slide 39: Spine Surgery Market is a Growing ~$12B Opportunity

    Slide 39: Spine Surgery Market is a Growing ~$12B Opportunity

    Spine Surgery Market is a Growing ~$12B Opportunity Major Trends Shaping Our Industry Market Opportunity Motion Preservation Devices Macro: Minimally Invasive Surgery (MIS) Bone Healing Technologies Core and Complex Solutions HSD ~$12B Increasing Adoption of Market Aging global MSD healthcare techno

  40. Slide 40: Product Overview

    Slide 40: Product Overview

    Product Overview Key Products Key Competitors • Spinal fusion implants, Core & instrumentation, and biologics Complex Solutions • Treats a spectrum of spinal pathologies ROI-C MaxAn Virage Vital TrellOss PrimaGen Bone • Non-invasive, nonsurgical technologies to help Healing promote bone healing Bone

  41. Slide 41: Drive Turnaround To Stabilize Then Grow

    Slide 41: Drive Turnaround To Stabilize Then Grow

    Drive Turnaround To Stabilize Then Grow Fund Future Innovation Key Growth Areas Base Business: MIS Core & Complex Spine Mobi-C The Tether Procedural Solutions Stabilize by Optimizing the Leverage Leadership Lead the Development of the Pull Through Implants by Portfolio, Driving Commercial Position t

  42. Slide 42: Core and Complex Portfolio

    Slide 42: Core and Complex Portfolio

    Support Surgeon Efforts to Treat a Spectrum of Spinal Pathologies Core and Complex Portfolio Support 77%[1] of Spine Procedures Today Base Business: Spine Cervical Core & Complex Spine Pathologies • Optimize portfolio by filling product gaps and • Degeneration streamlining offering • Innovate beyond

  43. Slide 43: Well-Positioned in Attractive Sub-Segments

    Slide 43: Well-Positioned in Attractive Sub-Segments

    Well-Positioned in Attractive Sub-Segments Cervical Disc Vertebral Body Minimally Invasive Replacement (CDR) Tethering (VBT) Surgery (MIS) for Degenerative Disc Disease for Pediatric Scoliosis Mobi-C The Tether MIS Procedural Solutions Restoring quality of life by Transforming scoliosis care for Ena

  44. Slide 44: Focus on Underdeveloped, High-Growth Markets

    Slide 44: Focus on Underdeveloped, High-Growth Markets

    Focus on Underdeveloped, High-Growth Markets Mobi-C The Tether MIS Procedural Solutions Cervical Disc Vertebral Body Minimally Invasive Replacement (CDR) Tethering (VBT) Surgery (MIS) for Degenerative Disc Disease for Pediatric Scoliosis Total Total Total Cervical Disc Tethering MIS Opportunity Oppo

  45. Slide 45: Expanding Patient Access to Best-in-Class Solutions

    Slide 45: Expanding Patient Access to Best-in-Class Solutions

    Expanding Patient Access to Best-in-Class Solutions Cervical Disc Replacement Vertebral Body Tethering Minimally Invasive Surgery (CDR) (VBT) (MIS) for Degenerative Disc Disease for Pediatric Scoliosis Mobi-C The Tether MIS Procedural Solutions Market leading cervical disc First-of-its-kind fusion-l

  46. Slide 46: Mobi-C: Restoring Quality of Life by Preserving Motion

    Slide 46: Mobi-C: Restoring Quality of Life by Preserving Motion

    Mobi-C: Restoring Quality of Life by Preserving Cervical Disc Opportunity Motion for Patients with Cervical Disc Disease $900M Served Cervical Disc Sub-segment $300M Mission Poorly Served Market: Faster Recovery: Better Outcomes: Economic Value: 2/3 of patients indicated for Cervical disc patients r

  47. Slide 47: Mobi-C: Restoring Quality of Life by Preserving Motion

    Slide 47: Mobi-C: Restoring Quality of Life by Preserving Motion

    Mobi-C: Restoring Quality of Life by Preserving Motion for Patients with Cervical Disc Disease

  48. Slide 48: The Tether: Transforming Scoliosis Care For Children

    Slide 48: The Tether: Transforming Scoliosis Care For Children

    Total The Tether: Transforming Scoliosis Care For Tether Opportunity Children By Preserving Their Motion $130M Served Tether Sub-segment $20M Mission Poorly Served Market: Motion Preserving: Promising Results: Faster Recovery: 90% of children eligible for Alternative to fusion Greater than 92% Retur

  49. Slide 49: The Tether: Transforming Scoliosis Care For Children

    Slide 49: The Tether: Transforming Scoliosis Care For Children

    The Tether: Transforming Scoliosis Care For Children By Preserving Their Motion

  50. Slide 50: MIS Procedural Solutions: Enabling Faster Recovery

    Slide 50: MIS Procedural Solutions: Enabling Faster Recovery

    Total MIS Procedural Solutions: Enabling Faster MIS Opportunity Recovery For Patients with Lumbar Spine Disease $4.7B Served MIS Sub-segment $1.9B Mission Poorly Served Market: Faster Recovery: Economic Value: 63% of patients with degenerative Patients recover faster after Shorter length of stay Spi

  51. Slide 51: Leverage Market Development Competencies to Expand our Opportunity

    Slide 51: Leverage Market Development Competencies to Expand our Opportunity

    Leverage Market Development Competencies to Expand our Opportunity We will leverage programs to support continued growth and development of Cervical Disc Non-fusion Treatment Minimally Invasive underserved, high- growth markets to Arthroplasty for Pediatric Scoliosis Surgery expand patient access to

  52. Slide 52: Transforming and Realigning Spine Business

    Slide 52: Transforming and Realigning Spine Business

    Transforming and Realigning Spine Business State of the Business Transformations Initiated Spine Revenue[1] ($M) Pre-2021 in 2021 • Stuck in the middle without a unique Focusing strategy on pursuing growth in identity and biased toward commoditized key sub-segments with differentiated $608 sub-segme

  53. Slide 53: Spine Key Takeaways

    Slide 53: Spine Key Takeaways

    • #6 share in an attractive ~$12B global market • Well-positioned with a global footprint and broad portfolio serving all segments of the Spine market • Turnaround base business to focus on three main growth drivers:  Mobi-C  The Tether  MIS Procedural Solutions Utilize proven market develo

  54. Slide 54: Financial Overview

    Slide 54: Financial Overview

    Financial Overview Rich Heppenstall Chief Financial Officer

  55. Slide 55: Historical Financial Performance Snapshot

    Slide 55: Historical Financial Performance Snapshot

    Historical Financial Performance Snapshot Revenue ($ millions) Adj. EBITDA[2] ($ millions) Spine Dental Related Party Transactions Total Spine and Dental Third Party Management Net Sales [1] Adjusted [3] $1,056 $1,009 34 $1,022 $912 $897 16 $753 5 $748 540 608 $139 529 $132 405 $100 $89 469 414 368

  56. Slide 56: Navigating COVID

    Slide 56: Navigating COVID

    Navigating COVID COVID significantly impacted Dental and Spine markets in 2020, ongoing uncertainty influencing Spine recovery in 2021 and early 2022 2020 2021 2022 outlook Significant disruption in Q1 and Q2 US: Dental offices generally operating Comparable to 2021 normally with limited staffing sh

  57. Slide 57: Foundational Strength of Underlying Business and Global Scale

    Slide 57: Foundational Strength of Underlying Business and Global Scale

    Foundational Strength of Underlying Business and Global Scale Support a Compelling Financial Opportunity Well-positioned Clinically Differentiated Global Reach and Enables Financial Global Leader in Brand Portfolio Broad Geographic Flexibility via Dental and Spine and Focused Footprint EBITDA and Fr

  58. Slide 58: Apply Disciplined Framework To Maximize Financial Opportunities

    Slide 58: Apply Disciplined Framework To Maximize Financial Opportunities

    Apply Disciplined Framework To Maximize Financial Opportunities • Commercial focus coupled with best-in-class medical training in high-growth markets Sales Growth • Leverage clinically superior products in dental and spine product platforms • Focus on digital dentistry to drive pull-through and spin

  59. Slide 59: 2022 Full-Year Financial Guidance

    Slide 59: 2022 Full-Year Financial Guidance

    2022 Full-Year Financial Guidance Flat to 2021E Third Party Revenue Revenue[1] ($1.0B) Flat to 50bps improvement to Adjusted EBITDA Mgmt. Adj. 2021E EBITDA Margin[2] (13.1%—13.6%) Adjusted EPS[3,4] $2.10—$2.30 Note: Management adjusted financial information gives effect to the separation as if the C

  60. Slide 60: Fueling Sustainable Sales Growth and Delivering Margin Expansion

    Slide 60: Fueling Sustainable Sales Growth and Delivering Margin Expansion

    Fueling Sustainable Sales Growth and Delivering Significant Margin Expansion Near-Term Targeting MSD Revenue Growth MSD% ï¬ Bolstering Our Teams Growthï¬ Strategic Prioritizationï¬ New Product Launches ï¬ Flat Manufacturing Footprint & Automation Growth 3 – 5 Years ï¬ New Product Innovation Near-ter

  61. Slide 61: Wrap Up

    Slide 61: Wrap Up

    Wrap Up Vafa Jamali Chief Executive Officer

  62. Slide 62: Positioned to Capitalize on Multiple Opportunities for Growth

    Slide 62: Positioned to Capitalize on Multiple Opportunities for Growth

    Positioned to Capitalize on Multiple Well-positioned in large and growing ~$20B global dental 1 Opportunities and spine markets for Growth 2 Comprehensive portfolio of trusted brands and products 3 Differentiated product profiles, supported by extensive clinical evidence MSD% Growth 4 Established co

  63. Slide 63: Question & Answer

    Slide 63: Question & Answer

    Question & Answer Vafa Jamali Indraneel Kanaglekar Rebecca Whitney Rich Heppenstall ZimVie SVP, President, SVP, President, ZimVie Chief Executive Officer Global Dental, Global Spine, Chief Financial Officer ZimVie ZimVie Page 63

  64. Slide 64: Thank you

    Slide 64: Thank you

    Flank you 2 ZimVie

  65. Slide 65: Disclaimer for Patient Testimonials

    Slide 65: Disclaimer for Patient Testimonials

    Disclaimer for Patient Testimonials NOT ALL PATIENTS ARE CANDIDATES FOR THE PRODUCTS AND/OR PROCEDURES PRESENTED HEREIN. RESULTS ARE NOT NECESSARILY TYPICAL, INDICATIVE, OR REPRESENTATIVE OF ALL RECIPIENT PATIENTS AND RESULTS MAY VARY. APPROPRIATE POST-OPERATIVE ACTIVITIES WILL DIFFER FROM PATIENT T

  66. Slide 66: Finance Appendix

    Slide 66: Finance Appendix

    FINANCE APPENDIX

  67. Slide 67: Non-GAAP Measures and Basis for Financial Presentation

    Slide 67: Non-GAAP Measures and Basis for Financial Presentation

    Non-GAAP Measures and Basis for Financial Presentation We have historically existed and functioned as part of the consolidated business of Zimmer Biomet. The accompanying financial information is prepared on a standalone basis and derived from Zimmer Biomet’s consolidated financial statements and ac

  68. Slide 68: 2022 Full-Year Financial Guidance Including One-Time Spin Metrics

    Slide 68: 2022 Full-Year Financial Guidance Including One-Time Spin Metrics

    2022 Full-Year Financial Guidance Including One-Time Spin Metrics Non-GAAP 2022 Guidance One-Time Spin Guidance Dental Spine Revenue growth (Annual growth rate) Flat to 2021 ($1.0B) + MSD—MSD Gross margin Mid 60’s% Mid 60’s% R&D as % of revenue 5%—6% 5%—6% SG&A as % of revenue 35%—40% 47.5%—52.5% Ad

  69. Slide 69: Historical Reported Combined Statements of Earnings

    Slide 69: Historical Reported Combined Statements of Earnings

    Historical Reported Combined Statements of Earnings (in $ millions) 3Q21 YTD 2019A 2020A (unaudited) Third party, net $1,021.6 $896.9 $748.2 Related party, net 33.9 15.5 4.8 Total net sales $1,055.5 $912.4 $753.0 Cost of products sold, excluding intangible asset amortization 309.4 302.7 256.4 Relate

  70. Slide 70: Reconciliation of Adjusted EBITDA

    Slide 70: Reconciliation of Adjusted EBITDA

    Reconciliation of Adjusted EBITDA (in $ millions) 3Q21 YTD 2019A 2020A (unaudited) Net loss of the Spine and Dental Businesses of Zimmer Biomet Holdings, Inc. ($28.0) ($179.1) ($34.6) Interest expense, net 0.1 0.3 0.3 (Benefit) provision for income taxes 0.2 (42.3) (1.3) Depreciation and amortizatio

Source: SEC EDGAR · 8-K filed Feb 7, 2022

More decks from ZimVie Inc